Carbidopa
Links shared publicly online about this topic
FDA Alert: Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review
drugs.com — “FDA Alert: Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review” View full resource at drugs.com
Most Recently Shared on March 31, 2010 at 11:30 pm By:
FDA Alert - Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review - http://bit.ly/czroqx
Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa)
medicalnewstoday.com — “Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced that it has acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets from Bristol-Myers Squibb Company (B” View full resource at medicalnewstoday.com
Most Recently Shared on May 1, 2010 at 1:08 pm By:
MNT Parkinson's News Health News
Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) http://mnt.to/3C2T #parkinsons
FDA Alert: Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
drugs.com — “FDA Alert: Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk” View full resource at drugs.com
Most Recently Shared on August 22, 2010 at 11:37 pm By:
FDA Alert - Ongoing Safety Review: Stalevo (carbidopa/levodopa and entacapone) - http://bit.ly/90MUk2
Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
fda.gov — “FDA evaluating clinical trial data that suggest patients taking drug may be at an increased risk for cardiovascular events compared to those taking carbidopa/levodopa” View full resource at fda.gov
Most Recently Shared on August 20, 2010 at 8:05 pm By:
Sandeep Pulim Health Communicator, Physician, and Doctor
#FDA Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk http://t.co/FTVOYRm
Evidence for the Use of Levodopa--Carbidopa--Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson--™s Disease | Neurology
touchneurology.com — “Evidence for the Use of Levodopa--Carbidopa--Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson--™s Disease” View full resource at touchneurology.com
Most Recently Shared on November 12, 2010 at 6:15 pm By:
touchNEURO Neurology and Health Site
Evidence for the Use of Levodopa–Carbidopa–Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson’s Disease http://ow.ly/363hl
Evidence for the Use of Levodopa"Carbidopa"Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson's Disease | Neurology
touchneurology.com — “Evidence for the Use of Levodopa"Carbidopa"Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson's Disease” View full resource at touchneurology.com
Most Recently Shared on October 23, 2009 at 2:41 pm By:
touchNEURO Neurology and Health Site
http://ow.ly/waxS Improve Motor Fluctuations in Parkinson’s Disease #neurology
Impax Pharmaceuticals Reports Positive Results Of Phase II Trial Of IPX066, A Novel Formulation Of Carbidopa-Levodopa For Parkinson's Disease
medicalnewstoday.com — “Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) reported the positive results from a recently completed Phase II trial of its late-stage Parkinson's D” View full resource at medicalnewstoday.com
Most Recently Shared on September 23, 2009 at 12:17 pm By:
MNT Parkinson's News Health News
Impax Pharmaceuticals Reports Positive Results Of Phase II Trial Of IPX066, A Novel Formulation Of Carbidopa-Lev.. http://bit.ly/lEn8x
Medical News: Cardio Risks Seen With Parkinson's Drug Trio, FDA Says - in Public Health & Policy, FDA General from MedPage Today
medpagetoday.com — “WASHINGTON -- Patients taking the Parkinson's drug combo carbidopa/levodopa and entacapone (Stalevo) may be at a higher risk for cardiovascular events such as myocardial infarction, stroke, and death,” View full resource at medpagetoday.com
Most Recently Shared on August 21, 2010 at 11:12 am By:
Cardio Risks Seen With Parkinson's Drug Trio, FDA Says: WASHINGTON (MedPage Today) -- Patients taking the Parkinso... http://bit.ly/9i1oWN
FDA evaluating cancer link in Parkinson's drug | Reuters
reuters.com — “NEW YORK (Reuters) - The U.S. Food and Drug Administration is evaluating clinical data that may suggest Novartis AG's Parkinson's disease treatment Stalevo is linked to an increased risk of prostate cancer. Data” View full resource at reuters.com
Most Recently Shared on April 1, 2010 at 2:01 am By:
Hisham Rana, MD Doctor and Physician
FDA evaluating prostate cancer link to Parkinson's drug Stalevo (carbidopa, levodopa, entacapone) http://bit.ly/b6CN8A - #health
Dystonia: Movement Disorders: Merck Manual Home Edition
merck.com — “Dystonia: Movement Disorders: Merck Manual Home Edition” View full resource at merck.com
Most Recently Shared on June 10, 2010 at 11:58 am By:
Movement Disorders: Learn about the symptoms, diagnosis, types, and treatment of dystonia http://bit.ly/a1jCOf
Impax Pharmaceuticals Completes Enrollment In APEX-PD Phase III Trial Of IPX066 In Parkinson's Disease
medicalnewstoday.com — “Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Pha” View full resource at medicalnewstoday.com
Most Recently Shared on April 18, 2010 at 12:05 pm By:
MNT Parkinson's News Health News
Impax Pharmaceuticals Completes Enrollment In APEX-PD Phase III Trial Of IPX066 In Parkinson's Disease http://mnt.to/3Bnv #parkinsons
Impax Pharmaceuticals Completes Enrollment In ADVANCE-PD Phase III Trial Of IPX066 In Parkinson's Disease
medicalnewstoday.com — “Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced that it has completed enrollment of its ADVANCE-PD trial. ADVANCE-PD is a multinational Pha” View full resource at medicalnewstoday.com
Most Recently Shared on August 27, 2010 at 1:00 pm By:
MNT Parkinson's News Health News
Impax Pharmaceuticals Completes Enrollment In ADVANCE-PD Phase III Trial Of IPX066 In Parkinson's Disease http://mnt.to/3HVQ #parkinsons
UPDATE 1-Glaxo buys rights to Parkinson's drug from Impax | Reuters
reuters.com — “* Impax gets $11.5 mln upfront, up to $175 mln in milestones * Extended release drug IPX066 in Phase III trials (Adds detail, background) LONDON, Dec 16 (Reuters) - GlaxoSmithKline ” View full resource at reuters.com
Most Recently Shared on December 16, 2010 at 2:22 pm By:
John Carroll Health Communicator
Impax will get $11.5M upfront and up to $175M in milestones from GSK on Parkinson's drug pact. http://reut.rs/eTqKgG
Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkinson's Disease - Drugs.com MedNews
drugs.com — “- IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of off time during waking hours A” View full resource at drugs.com
Most Recently Shared on August 15, 2011 at 4:03 pm By:
Drugs and Devices OW OW Health
Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkins... http://t.co/UVzIYCu #drug
Neurology Article | Parkinson disease
mdlinx.com — “Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being” View full resource at mdlinx.com
Most Recently Shared on May 31, 2011 at 8:05 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation e... http://bit.ly/mjz7Sn #neuro
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
MNT Parkinson's News
The latest parkinson's disease news published daily. Articles from research centers, universities and prestigious journals.
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
Advertisement
